Related Experiment Video
Updated: Jul 24, 2025
11:31
Isolation of Peritoneum-derived Mast Cells and Their Functional Characterization with Ca2+-imaging and Degranulation Assays
Published on: July 4, 2018
12.4K
Is lirentelimab the 'magic bullet' to fight pathological mast-cell activation in systemic mastocytosis?
Stéphane Barete1, Michel Arock1
1Reference center for mastocytosis (CEREMAST), AP-HP, GH Pitié-Salpêtrière, 47-83 bd de l'Hôpital 75013 Paris and Sorbonne Université, Paris.
The British Journal of Dermatology
|July 5, 2023
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
354
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
354
01:19Antiasthma Drugs: Leukotriene Modifiers
369
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
369